Literature DB >> 18335188

Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette.

Matthias Leisegang1, Boris Engels, Peter Meyerhuber, Elisa Kieback, Daniel Sommermeyer, Shao-An Xue, Simone Reuss, Hans Stauss, Wolfgang Uckert.   

Abstract

The transfer of T cell receptor (TCR) genes allows to endow T cells with a new antigen specificity. For clinical applications of TCR-redirected T cells, efficient functional expression of the transgenic TCR is a key prerequisite. Here, we compared the influence of the transgene cassette on the expression and function of the murine TCR P14 (recognizing a LCMV gp33 epitope) and the human TCR WT-1 (recognizing an epitope of the tumor-associated antigen WT-1). We constructed different vectors, in which TCRalpha- and beta-chain genes were either (a) linked by an internal ribosomal entry site (IRES), (b) combined by a 2A peptide, or (c) introduced into two individual retroviral constructs. While in a TCR-deficient T cell line TCR P14 was expressed equally well by all constructs, we found that IRES- but not 2A-employing TCR expression is hampered in a TCR-bearing cell line and in primary murine T cells where the transgenic TCR has to compete with endogenous TCR chains. Similarly, 2A-linked TCR WT-1 genes yielded highest expression and function as measured by tetramer binding and peptide-specific IFN-gamma secretion. Differences in expression were independent of copy number integration as shown by real-time PCR. Thus, linking TCRalpha- and beta-chain genes by a 2A peptide is superior to an IRES for TCR expression and T cell function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18335188     DOI: 10.1007/s00109-008-0317-3

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  36 in total

1.  Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell antigens.

Authors:  J Karttunen; S Sanderson; N Shastri
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

2.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

3.  Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells.

Authors:  Kirsten B J Scholten; Duco Kramer; Esther W M Kueter; Marcus Graf; Thomas Schoedl; Chris J L M Meijer; Marco W J Schreurs; Erik Hooijberg
Journal:  Clin Immunol       Date:  2006-02-02       Impact factor: 3.969

4.  Efficiency of T-cell receptor expression in dual-specific T cells is controlled by the intrinsic qualities of the TCR chains within the TCR-CD3 complex.

Authors:  Mirjam H M Heemskerk; Renate S Hagedoorn; Menno A W G van der Hoorn; Lars T van der Veken; Manja Hoogeboom; Michel G D Kester; Roel Willemze; J H Frederik Falkenburg
Journal:  Blood       Date:  2006-09-12       Impact factor: 22.113

5.  Derivation of a T cell hybridoma variant deprived of functional T cell receptor alpha and beta chain transcripts reveals a nonfunctional alpha-mRNA of BW5147 origin.

Authors:  F Letourneur; B Malissen
Journal:  Eur J Immunol       Date:  1989-12       Impact factor: 5.532

6.  Designer T cells by T cell receptor replacement.

Authors:  Daniel Sommermeyer; Julia Neudorfer; Monika Weinhold; Matthias Leisegang; Boris Engels; Elfriede Noessner; Mirjam H M Heemskerk; Jehad Charo; Dolores J Schendel; Thomas Blankenstein; Helga Bernhard; Wolfgang Uckert
Journal:  Eur J Immunol       Date:  2006-11       Impact factor: 5.532

7.  Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen.

Authors:  H Pircher; K Bürki; R Lang; H Hengartner; R M Zinkernagel
Journal:  Nature       Date:  1989-11-30       Impact factor: 49.962

8.  Redirecting human T lymphocytes toward renal cell carcinoma specificity by retroviral transfer of T cell receptor genes.

Authors:  Boris Engels; Elfriede Noessner; Bernhard Frankenberger; Thomas Blankenstein; Dolores J Schendel; Wolfgang Uckert
Journal:  Hum Gene Ther       Date:  2005-07       Impact factor: 5.695

9.  Retroviral vector-mediated expression of HoxB4 in hematopoietic cells using a novel coexpression strategy.

Authors:  H Klump; B Schiedlmeier; B Vogt; M Ryan; W Ostertag; C Baum
Journal:  Gene Ther       Date:  2001-05       Impact factor: 5.250

10.  Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth.

Authors:  Y Oji; H Ogawa; H Tamaki; Y Oka; A Tsuboi; E H Kim; T Soma; T Tatekawa; M Kawakami; M Asada; T Kishimoto; H Sugiyama
Journal:  Jpn J Cancer Res       Date:  1999-02
View more
  56 in total

1.  Protective capacity of virus-specific T cell receptor-transduced CD8 T cells in vivo.

Authors:  Katja Mueller; Anne von Mässenhausen; Ulrike Aichele; Lilian Stärck; Matthias Leisegang; Wolfgang Uckert; Hanspeter Pircher
Journal:  J Virol       Date:  2012-07-11       Impact factor: 5.103

2.  Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.

Authors:  D H Aggen; A S Chervin; T M Schmitt; B Engels; J D Stone; S A Richman; K H Piepenbrink; B M Baker; P D Greenberg; H Schreiber; D M Kranz
Journal:  Gene Ther       Date:  2011-07-14       Impact factor: 5.250

3.  MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors.

Authors:  Matthias Leisegang; Susanne Wilde; Stefani Spranger; Slavoljub Milosevic; Bernhard Frankenberger; Wolfgang Uckert; Dolores J Schendel
Journal:  J Clin Invest       Date:  2010-10-11       Impact factor: 14.808

4.  Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.

Authors:  Lucia Poncette; Xiaojing Chen; Felix Km Lorenz; Thomas Blankenstein
Journal:  J Clin Invest       Date:  2018-12-10       Impact factor: 14.808

5.  A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days.

Authors:  Eiji Kobayashi; Eishiro Mizukoshi; Hiroyuki Kishi; Tatsuhiko Ozawa; Hiroshi Hamana; Terumi Nagai; Hidetoshi Nakagawa; Aishun Jin; Shuichi Kaneko; Atsushi Muraguchi
Journal:  Nat Med       Date:  2013-10-13       Impact factor: 53.440

6.  Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.

Authors:  Raquel Gomez-Eerland; Bastiaan Nuijen; Bianca Heemskerk; Nienke van Rooij; Joost H van den Berg; Jos H Beijnen; Wolfgang Uckert; Pia Kvistborg; Ton N Schumacher; John B A G Haanen; Annelies Jorritsma
Journal:  Hum Gene Ther Methods       Date:  2014-09-22       Impact factor: 2.396

Review 7.  Immunomodulation in the treatment of haematological malignancies.

Authors:  Michela Cesco-Gaspere; Emma Morris; Hans J Stauss
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

8.  PLAC1-specific TCR-engineered T cells mediate antigen-specific antitumor effects in breast cancer.

Authors:  Qiongshu Li; Muyun Liu; Man Wu; Xin Zhou; Shaobin Wang; Yuan Hu; Youfu Wang; Yixin He; Xiaoping Zeng; Junhui Chen; Qubo Liu; Dong Xiao; Xiang Hu; Weibin Liu
Journal:  Oncol Lett       Date:  2018-02-16       Impact factor: 2.967

9.  Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.

Authors:  Belinda Berdien; Henrike Reinhard; Sabrina Meyer; Stefanie Spöck; Nicolaus Kröger; Djordje Atanackovic; Boris Fehse
Journal:  Hum Vaccin Immunother       Date:  2013-02-21       Impact factor: 3.452

Review 10.  Strategies to genetically engineer T cells for cancer immunotherapy.

Authors:  Timothy T Spear; Kaoru Nagato; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-05-02       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.